- Home
- COYA vs CATX Comparison
COYA vs CATX Comparison
Compare COYA & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | CATX |
|---|---|---|
| Founded | 2020 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.7M | 97.7M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | COYA | CATX |
|---|---|---|
| Price | $3.24 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $15.21 | $9.93 |
| AVG Volume (30 Days) | 166.4K | ★ 4.1M |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $335.89 | $46.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $2.72 | $0.78 |
| 52 Week High | $6.62 | $6.16 |
Technical Indicators
Market Signals| Indicator | COYA | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 23.09 |
| Support Level | N/A | N/A |
| Resistance Level | $5.17 | $2.40 |
| Average True Range (ATR) | 0.35 | 0.21 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 32.91 | 4.07 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.